Biogen (BIIB) Short-term Investments (2009 - 2026)

Biogen's Short-term Investments history runs 17 years deep, the most recent figure standing at $900.0 million for Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $900.0 million; the TTM figure through Mar 2026 stood at $900.0 million (changed N/A YoY), while the FY2025 annual figure was $807.2 million, changed N/A from the prior year.
• Short-term Investments for Q1 2026 stood at $900.0 million, up from $807.2 million in the prior quarter.
• The five-year high for Short-term Investments was $3.5 billion in Q2 2023, with the low at $97.6 million in Q3 2025.
• The 4-year median for Short-term Investments is $1.5 billion (2022), against an average of $1.6 billion.
• Peak annual rise in Short-term Investments reached 64.37% in 2022, while the deepest fall reached 12.58% in 2022.
• Biogen's Short-term Investments stood at $1.5 billion in 2022, then jumped by 134.85% to $3.5 billion in 2023, then tumbled by 76.67% to $807.2 million in 2025, then advanced by 11.5% to $900.0 million in 2026.
• Business Quant data shows BIIB's Short-term Investments at $900.0 million in Q1 2026, $807.2 million in Q4 2025, and $97.6 million in Q3 2025.